Site icon pharmaceutical daily

GRAIL in $390 Million series D financing round

Grail logo. Source: grail.com

MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a $390 million Series D financing round.

New investors including Public Sector Pension Investment Board (PSP Investments) and Canada Pension Plan Investment Board (CPP Investments), as well as two undisclosed investors, joined existing backers including Illumina, Inc. in this round of funding.

Since early 2016, GRAIL has raised more than $1.9 billion in four rounds of equity financing to pursue reducing cancer mortality worldwide through multi-cancer early detection.

“GRAIL is making significant progress with our blood-based, multi-cancer early detection test,” said Hans Bishop, Chief Executive Officer at GRAIL. “Nearly 80 percent of cancer deaths result from cancers for which there is no screening test today, and GRAIL’s mission is to change that through the early detection and localization of more than 50 cancers. Enabling this through a single blood draw could improve patient access and adherence to cancer screening and address disparities in cancer care by improving access for rural, vulnerable, and under-served populations. We are delighted that such a high-quality group of investors share our vision and recognize the public health benefits of our technology.”

The Series D funding adds to the company’s balance sheet and will support continued development and commercialization of GRAIL’s multi-cancer early detection blood test. Since early 2016, GRAIL has raised more than $1.9 billion in four rounds of equity financing to pursue reducing cancer mortality worldwide through multi-cancer early detection.

Exit mobile version